Stock ALPN ALPINE IMMUNE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
64.97 USD +0.02% Intraday chart for Alpine Immune Sciences, Inc. -.--% +240.87%
May. 20 Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index CI
May. 20 Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 71.38 299.9 404.7 337.5 1,106 4,457 - -
Enterprise Value (EV) 1 71.38 299.9 404.7 114.1 778.1 4,081 4,155 4,034
P/E ratio -1.68 x -9.4 x -6.99 x -4.25 x -29.8 x -48.1 x -36.8 x -30.9 x
Yield - - - - - - - -
Capitalization / Revenue 41 x 32.1 x 17.3 x 11.2 x 18.8 x 252 x 219 x 360 x
EV / Revenue 41 x 32.1 x 17.3 x 3.79 x 13.2 x 231 x 204 x 326 x
EV / EBITDA - - -8,219,083 x -1,957,958 x -17,816,034 x - - -
EV / FCF - - - - - -42.3 x -36 x -30 x
FCF Yield - - - - - -2.36% -2.78% -3.33%
Price to Book - - - 1.88 x - - - -
Nbr of stocks (in thousands) 18,588 23,803 29,220 45,914 58,002 68,598 - -
Reference price 2 3.840 12.60 13.85 7.350 19.06 64.97 64.97 64.97
Announcement Date 3/30/20 3/18/21 3/17/22 3/23/23 3/18/24 - - -
1USD in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1.74 9.335 23.44 30.06 58.88 17.7 20.32 12.37
EBITDA - - -49.24 -58.25 -43.67 - - -
EBIT 1 -43.57 -28.75 -49.86 -58.15 -44.25 -103.4 -129.8 -148.7
Operating Margin -2,504.25% -307.97% -212.68% -193.41% -75.16% -584.04% -638.64% -1,202%
Earnings before Tax (EBT) 1 -41.85 -27.95 -50.42 -55.43 -32.08 -96.54 -123.5 -144.1
Net income 1 -41.85 -27.94 -50.33 -57.76 -32.18 -97.32 -115.5 -145.3
Net margin -2,405.29% -299.3% -214.7% -192.13% -54.66% -549.96% -568.25% -1,174.48%
EPS 2 -2.280 -1.340 -1.980 -1.730 -0.6400 -1.350 -1.766 -2.104
Free Cash Flow 1 - - - - - -96.45 -115.4 -134.3
FCF margin - - - - - -545.03% -568.05% -1,085.6%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/30/20 3/18/21 3/17/22 3/23/23 3/18/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - 223 327 376 302 423
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -96.5 -115 -134
ROE (net income / shareholders' equity) - - - -38.5% -12.7% - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - 3.900 - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - - - - - 2.25 2.75 3.25
Capex / Sales - - - - - 12.71% 13.53% 26.27%
Announcement Date 3/30/20 3/18/21 3/17/22 3/23/23 3/18/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Alpine Immune Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALPINE IMMUNE SCIENCES, INC. Stock Alpine Immune Sciences, Inc.
+240.87% 4.46B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALPN Stock
  4. Financials Alpine Immune Sciences, Inc.